Marksans Pharma is making global moves again. The company’s UK unit just got the green signal from the UK Medicines and Healthcare products Regulatory Agency (UKMHRA) to sell its Oxybutynin oral solution in the UK.
Oxybutynin is used to treat overactive bladder (OAB). It helps people who deal with symptoms like frequent urination, sudden urges to pee, and sometimes even accidental leaks.
This is a real quality-of-life issue for millions, especially the elderly. And now, with this approval, Marksans Pharma is entering the ring with a generic solution that could change how OAB is managed in the UK.
This isn’t Marksans’ first rodeo. The pharma player has built a strong name in the global market by sticking to what it does best — making high-quality generic drugs that meet international standards. Its manufacturing plants in India, the US, and the UK are certified by big-name regulators like the USFDA, UKMHRA, and TGA from Australia.
The company has a wide product range, covering major health areas like cardiovascular, central nervous system, diabetes, pain relief, stomach health, and allergies. And now, with Oxybutynin added to its UK offerings, Marksans is expanding its footprint in urology and bladder care too.
This latest nod from the UKMHRA is not just a regulatory tick. It’s a vote of confidence in Marksans Pharma’s quality, consistency, and global standards. And the numbers seem to back that up.
In Q4 FY25, Marksans Pharma reported a 15.7% jump in consolidated net profit, reaching ₹90.55 crore. Revenue also surged by 26.5% to ₹708.46 crore compared to the same quarter last year. The market took notice — the stock rose 0.36% to ₹251.30 on the BSE.
For a company that’s always stayed under the radar, Marksans is now grabbing global attention. And rightly so. Getting a nod from UKMHRA is no small feat — especially for a generic oral solution targeting a chronic condition like OAB. It shows how far Indian pharma has come — and how players like Marksans are rewriting the rules.
With a sharp growth path, rising investor interest, and new approvals rolling in, Marksans Pharma is no longer just a silent performer — it’s a confident global contender.
Also Read L&T May Issue Another ESG Bond After Successful ₹5,000 Cr Launch
